medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2017, Number 4

<< Back Next >>

Rev Esp Med Quir 2017; 22 (4)

Expression of p16 and cyto-colpohistological correlation in cervical lesions in patients from Puerto Vallarta, Jalisco

Moreno-Ramírez CE, Curiel-Beltrán JA; Cruz-Toraya OR, Arisbeth-Villanueva M, Morales-Flores EA, Castro-Herrera GA, Nande-Vázquez EM, Torres-Vázquez JA, Ramos-Gallardo G, Corona-Hernández JM

Language: Spanish
References: 39
Page: 153-161
PDF size: 209.95 Kb.


ABSTRACT

This study aims to evaluate the correct cytologic-colposcope- histologic diagnostic and compares the expression of p16 by immunohistochemistry in conventional cytology and biopsies of recent lesions, the samples were obtained from the colposcope examination of patients with LEI cytology diagnostic, pretending to evaluate its use as a diagnostic support tool.
49 patients between 20 -60 years old were include, every patient came to consultation for colposcope review and biopsy with a previous LEI cytology report, immunohistochemically were realized to cytological samples and biopsies to determine overexpression of the p16 protein.
32 cases with diagnostic for LEIBG (65.3%) were reported from de 49 samples of cytology’s cervix-vaginal and cervix histologist, 16 cases from LEIAG diagnostic (32.7%), and one case with invasive squamous carcinoma (2%); there was a diagnostic correlation with histologic-colposcope in 43 cases (87.75%) p›0.001 and there wasn’t in 6 cases (12.25%), there were found a positive overexpression to p16 in 5 cases (15.6%) also the samples with diagnostic report from LEIAG and CEI there was a positive overexpression of 100% in all the cases.
The present study found a strong correlation between a better diagnostic assurance and the correlation cytologic-colposcope- histologic analysis. The immunohistochemistry probes to evaluate overexpression of P16 is useful when there are diagnostic differences between LEIBG and LEIAG, decreasing the inter-examination variation. In this study we found that in conventional cytology there was a similar overexpression with biopsies, demonstrating that in abnormal routine cytology the staining with p16 will be useful.


REFERENCES

  1. International Agency for Research on Cancer. Cervix Cancer Screening. Lyon: IARC Press; 2005.

  2. Parkin DM, Passini P, Ferlay J. Estimates of worldwide incidente of 25 major cancers in 1990. Int J Cancer. 1999;54:827-41.

  3. GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016t;388(10053):1659-724.

  4. Secretaría de Salud [Internet]. México; 2015 [fecha de consulta 14 de octubre de 2016]. Cáncer del cuello uterino y VPH. Disponible en: http://www.gob. mx/salud/acciones-y-programas/cancer-de-cuello-uterino

  5. Said HM, Ahmed K, Burnett R, et al. HPV genotypes in women with squamous intraepithelial lesions and normal cervixes participating in a community based microbiocide study in Pretoria, South Africa. J Clin Virol. 2009;44(4):318-21.

  6. Thomas J, Castle P, Behrens C, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013;208(184):184.e1-11.

  7. Flores-Miramontes MG, Torres-Reyes LA, Aguilar-Lemarroy A, et al. Prevalencia de genotipos de VPH en México y en el mundo detectados mediante Linear Array. Rev Med Inst Mex Seguro Soc. 2015;53 (Suppl 2):122-30.

  8. Tsoumpou I, Arbyn M, Kyrgiou M, et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: A systematic review and meta-analysis. Cancer Treat Rev. 2009;35:210-20.

  9. Kurshumliu F, Thorns C, Gashi-Luci L. p16INK4A in routine practice as a marker of cervical epithelial neoplasia. Gynecol Oncol. 2009;115(2009):127-31.

  10. Allia E, Ronco G, Coccia A, et al. Interpretation of p16INK4a/Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology. Cancer Cytopathol. 2015;123:212-18.

  11. Chen YY, You SL, Koong SL, et al. Screening frequency and atypical cells and the prediction of cervical cancer risk. Obstet Gynecol. 2014;123(5): 1003-11.

  12. Thomas J, Castle P, Behrens C, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013;208(184):184.e1-11.

  13. Yang DG, Liu L, Zheng XY. Cyclin-dependent kinase inhibitor p16INK4a and telomerase may co-modulate endothelial progenitor cells senescence. Ageing Research Reviews. 2008;7:137-146.

  14. El-Ghobashy A, Shaaban AM, Innes J, et al. Differential expression of cyclin-dependent kinase inhibitors and apoptosis-related proteins in endocervical lesions. Eur J Cancer. 2007;43:2011-8.

  15. Kurshumliu , Thorns , Gashi-Luci. p16INK4A in routine practice as a marker of cervical epithelial neoplasia. Gynecologic Oncology. 2009;115(2009):127-131.

  16. Gertych A, Joseph AO, Walts AE, et al. Automated detection of dual p16/Ki67 nuclear immunoreactivity in liquid-based Pap tests for improved cervical risk stratification. Ann Biomed Eng. 2012;40(5):1192-204.

  17. Wensveen C, Kagie M, Nagelkerke N, et al. Interobserver agreement on interpreting hand drawings of colposcopy in women with borderline cytology to predict high-grade lesions. Eur J Obstet Gynecol Reprod Biol. 2007;135:123-6.

  18. Del Pino M, Rodríguez-Carunchio L, Alonso I, et al. Clinical, colposcopic and pathlogical characteristics of cervical and vaginal high-grade lesions negative for HPV by Hybrid Capture 2. Gynecologic Oncology. 2011;122:515-20.

  19. Genovés J, Frances A, Gemma M, et al. Human papillomavirus detection and p16INK4a expression in cervical lesions: a comparative study. Human Pathology. 2014;45(4):826-33.

  20. Solomon D. The Bethesda system for reporting cervical/vaginal cytological diagnosis.J Am Med Assoc. 1989;262:931-4.

  21. Kisser A, Zechmeister-Koss I. A systematic review of p16/Ki-67 immuno-

  22. Gomez FJT, Machín PF, Cala CR, et al. Papel de p16 en lesiones preinvasivas e invasivas de cáncer de cuello uterino. Aplicación de la técnica a citología convencional. Prog Obstet Ginecol. 2011;54(4):193-203.

  23. Ding L, Chen Q, Fan, et al. Application of a time-resolved fluoroimmunoassay for detection of p16INK4a in cervix. Ann Diagn Pathol. 2017;29:7-10.

  24. Tatti S, Bornstein J, Prendiville W. Colposcopy: a global perspective instroduction of the new IFCPC colposcopy terminology. Obstetric Gynecologic Clinic N Am. 2013;40:235-50.

  25. Tsoumpou I, Arbyn M, Kyrgiou M, et al. p16INK4a immunostaining in cytological and histological specimens from the uterine cervix: A systematic review and meta-analysis. Cancer Treat Rev. 2009;35:210-20.

  26. Jeronimo J, Massad S, Schiffman M; National Institutes of Health/American Society for Colposcopy and Cervical Pathology (NIH/ASCCP) Research Group. Visual appearance of the uterine cervix. Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type. Am J Obstet Gynecol. 2007;197: 47.e1-8.

  27. Tan J, Wrede D. New technologies and advances in colposcopic assessment. Best Pract Res Clin Obstet Gynaecol. 2011;25:667-77.

  28. Bergeron C, Ordi J, Schmidt D, et al. Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol. 2010;133:395-406.

  29. Cheng-Chieh C, Lee-Wen H, Chyi-Huey B, et al. Predictive value of p16/Ki-67 immunocytochemistry for triage of women with abnormal Papanicolaou test in cervical cancer screening: a systematic review and meta-analysis. Ann Saudu Med. 2016;36:245-51

  30. Klaes R, Benner A, Friedrich T, et al. p16 INK4a improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol. 2002;26:1389-99.

  31. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16ink4a as specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92:276-84.

  32. Adamopoulou M, Kalkani E, Charvalos E, et al. Comparison of cytology, colposcopy, HPV typing and biomarker analysis in cervical neoplasia. Anticancer Research. 2009;29:3401-10.

  33. Diaz-Amézquita E, Martínez N, Dragustinovis I. Correlación citológica-colposcópica e histológica de lesiones de bajo y alto grado en cérvix. Rev Hosp Gral Dr. M Gea González 2006;7(2):54-8.

  34. Gajanin Z, Vilendecic R, Ecim Zlojutro V, et al. Significance of immunohistochemical expression of p16INK4a in the differentiation of inflammatory and preneoplastic cervical lesions. Srp Arh Celok Lek. 2015;143:42-9.

  35. Gertych A, Joseph AO, Walts A, et al. Automated detection of dual p16/Ki67 nuclear immunoreactivity in liquid-based Pap tests for improved cervical cancer risk stratification. Ann Biomed Eng. 2012;40(5):1192-204.

  36. Zeqiri F, Paçarada M, Kongjeli K, et al. The importance of colposcopy in the prevention of cervical malignancies. Int J Gynaecol Obstet. 2010;110:149-62.

  37. Gomez FJT, Machín PF, Cala CR, et al. Papel de p16 en lesiones preinvasivas e invasivas de cáncer de cuello uterino. Aplicación de la técnica a citología convencional. Prog Obstet Ginecol. 2011;54(4):193-203.

  38. Van Bogaert LJ. P16INK4a immunocytochemistry/immunohistochemistry: need for scoring uniformization to be clinically useful in gynecological pathology. Annals. 2012;16:422-6.

  39. Bergeron C, Ronco G, Reuschenbach M, et al. The clinical impact of using p16INK4a immunochemistry in cervical histopathology and cytology: An update of recent developments. Int J Cancer. 2015;136:2741-51.




2020     |     www.medigraphic.com